Paul La Rosée (P La Rosée)

ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 15

Top Venues

Leukemia

Blood

Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH May 01 2016

Germany

Director :: Klinik für Innere Medizin II

Friedrich-Schiller-University Jul 01 2009

Germany

Faculty :: Hematology/Oncology

Publications

Johanna Knauft, Thomas Schenk, Thomas Ernst, Ulf Schnetzke, Andreas Hochhaus, Paul La Rosée, Sebastian Birndt
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia 38 (2) (2024)
Johanna Knauft, Thomas Schenk, Thomas Ernst, Ulf Schnetzke, Andreas Hochhaus, Paul La Rosée, Sebastian Birndt
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia 38 (2) (2024)
Johanna Knauft, Thomas Schenk, Thomas Ernst, Ulf Schnetzke, Andreas Hochhaus, Paul La Rosée, Sebastian Birndt
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia 38 (2) (2024)
Johanna Knauft, Thomas Schenk, Thomas Ernst, Ulf Schnetzke, Andreas Hochhaus, Paul La Rosée, Sebastian Birndt
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia 38 (2) (2024)
Johanna Knauft, Thomas Schenk, Thomas Ernst, Ulf Schnetzke, Andreas Hochhaus, Paul La Rosée, Sebastian Birndt
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia (2024)
Johanna Knauft, Thomas Schenk, Thomas Ernst, Ulf Schnetzke, Andreas Hochhaus, Paul La Rosée, Sebastian Birndt
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia 38 (2) (2024)
Johanna Knauft, Thomas Schenk, Thomas Ernst, Ulf Schnetzke, Andreas Hochhaus, Paul La Rosée, Sebastian Birndt
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia 38 (2) (2024)
J Hammersen, Sebastian Birndt, K Döhner, Philipp Alexander Reuken, A Stallmach, P Sauerbrey, F La Rosée, M Pfirrmann, C Fabisch, M Weiss, K Träger, H Bremer, S Russo, Gerald Illerhaus, D Drömann, S Schneider, Paul La Rosée, Andreas Hochhaus
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial. Leukemia (2023)
Andrés José Maria Ferreri, Kate Cwynarski, Elisa Pulczynski, Christopher P Fox, Elisabeth Schorb, Claudia Celico, Monica Falautano, Alessandro Nonis, Paul La Rosée, Mascia Binder, Alberto Fabbri, Fiorella Ilariucci, Mauro Krampera, Alexander Roth, Claire Hemmaway, Peter W Johnson, Kim M Linton, Tobias Pukrop, Jettes Sønderskov Gørløv, Monica Balzarotti, Georg Hess, Ulrich Bernd Keller, Stephan Stilgenbauer, Jens Peter Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Manuela Zanni, Stefan W Krause, Hans J Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Lorenz Thurner, Giuseppina Cabras, Elsa Pennese, Maurilio Ponzoni, Martina Deckert, Letterio S Politi, Juergen Finke, Antonella Ferranti, Kelly Cozens, Elvira Burger, Nicoletta Ielmini, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, null null
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 36 (7) (2022)
Paul La Rosée
Detecting HLH in hematologic malignancies. Blood 139 (7) (2022)
Philipp Alexander Reuken, Maria Madeleine Rüthrich, A Hochhaus, J Hammersen, Michael Bauer, Paul La Rosée, F La Rosée, Andreas Stallmach
The impact of specific cytokine directed treatment on severe COVID-19. Leukemia 35 (12) (2021)
F La Rosée, H C Bremer, I Gehrke, A Kehr, A Hochhaus, Sebastian Birndt, M Fellhauer, M Henkes, B Kumle, S G Russo, Paul La Rosée
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia 34 (7) (2020)
Paul La Rosée, AnnaCarin Horne, Melissa Hines, Tatiana von Bahr Greenwood, Rafal Machowicz, Nancy Berliner, Sebastian Birndt, Juana Gil-Herrera, Michael Girschikofsky, Michael B Jordan, Ashish R Kumar, Jan A M van Laar, Gunnar Lachmann, Kim E Nichols, Athimalaipet Vaidyanathan Ramanan, Yini Wang, Zhao Wang, Gritta Janka, Jan-Inge Henter
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133 (23) (2019)
Paul La Rosée
Alleviating the storm: ruxolitinib in HLH. Blood 127 (13) (2016)
Paul La Rosée
First prospective clinical trial in adult HLH. Blood 126 (19) (2016)

Paul La Rosée.css-eqlu8i{font-size:small;padding-left:4px;} (P La Rosée)

Publication Activity (10 Years)

Top Topics

Top Venues

Paul La Rosée (P La Rosée)